Toxicity of Organometal(loids)View this Special Issue
Research Article | Open Access
Marc Bartel, Franziska Ebert, Larissa Leffers, Uwe Karst, Tanja Schwerdtle, "Toxicological Characterization of the Inorganic and Organic Arsenic Metabolite Thio- in Cultured Human Lung Cells", Journal of Toxicology, vol. 2011, Article ID 373141, 9 pages, 2011. https://doi.org/10.1155/2011/373141
Toxicological Characterization of the Inorganic and Organic Arsenic Metabolite Thio- in Cultured Human Lung Cells
We synthesised and toxicologically characterised the arsenic metabolite thiodimethylarsinic acid (thio-). Successful synthesis of highly pure thio- was confirmed by state-of-the-art analytical techniques including -NMR, HPLC-FTMS, and HPLC-ICPMS. Toxicological characterization was carried out in comparison to arsenite and its well-known trivalent and pentavalent methylated metabolites. It comprised cellular bioavailability as well as different cytotoxicity and genotoxicity end points in cultured human A549 lung cells. Of all arsenicals investigated, thio- exerted the strongest cytotoxicity. Moreover, thio- did not induce DNA strand breaks and an increased induction of both micronuclei and multinucleated cells occurred only at beginning cytotoxic concentrations, indicating that thio- does not act via a genotoxic mode of action. Finally, to assess potential implications of thio- for human health, further mechanistic studies are urgently necessary to identify the toxic mode of action of this highly toxic, unusual pentavalent organic arsenical.
Inorganic arsenic is a well-documented human carcinogen (IARC, Group 1) causing tumors in the lung, skin, and bladder [1, 2]. However, the underlying molecular mechanisms of inorganic arsenic-induced carcinogenicity are still to be elucidated, especially since inorganic arsenic, unlike other classical chemical carcinogens, does neither induce direct DNA damage nor mutagenicity at exposure-relevant concentrations . Besides the contribution of its metabolism, a variety of further potential mechanisms are discussed, including the induction of genetic damage via oxidative mechanisms [4–6], epigenetic dysregulation , and interaction with the cellular DNA damage response and DNA repair , resulting in comutagenic and cocarcinogenic effects .
For the general population, human diet is the primary source of both total arsenic and inorganic arsenic intake. The European Food Safety Authority (EFSA) Panel on Contaminants in the Food Chain and the Joint Food and Agriculture Organization/World Health Organisation (FAO/WHO) Expert Committee on Food Additives (JECFA) have concluded in their recent scientific opinions on arsenic that risks to human health related to the presence of inorganic arsenic in food cannot be excluded. In 2010, the JECFA withdrew the previous provisional tolerable weekly intake (PTWI) [9–11]. Furthermore, the EFSA Panel emphasized the necessity for toxicological characterization of seafood and fish-related organic arsenicals, including arsenosugars and arsenolipids, for which to date no toxicological data exist . In contrast to arsenobetaine, which is the main arsenic compound in fish, but is not metabolized by humans, arsenosugars and arsenolipids are extensively biotransformed to a multitude of arsenic metabolites [12, 13]. Some of these compounds are believed to be highly toxic and thus it cannot be excluded that seafood and fish-related organic arsenic species present risks to human health.
Regarding in vitro toxicity of the well-known and partly toxicologically characterised human inorganic arsenic metabolites monomethylarsinous (MMAIII), dimethylarsinous (DMAIII), monomethylarsonic (MMAV), and dimethylarsinic (DMAV) acid, the trivalent metabolites exert stronger cytotoxicity, as well as direct and indirect genotoxicity as compared to arsenite [14–21] in most cellular and subcellular test systems. Therefore, trivalent methylated arsenicals are generally believed to strongly contribute to inorganic arsenic-induced genotoxicity and, most likely, carcinogenicity.
Thiodimethylarsinic acid (thio-DMAV, [(CH3)2As(S)OH], also named dimethylmonothio-arsinic acid, DMMTAV or DMTAV) is the pentavalent sulfur analogue of DMAV and a metabolite of organic as well as inorganic arsenicals. The first identification of thio-DMAV as a mammalian arsenic metabolite was obtained in urine and wool extract from a sheep naturally consuming large amounts of arsenosugars through seaweed . In this paper, the group of Feldmann also discussed the serious problem that thio-DMAV may have been misidentified as DMAIII in human urine samples before and, therefore, might have escaped detection in many samples so far [22, 23]. Indeed, thio-DMAV has later been identified in human urine after exposure towards arsenosugars as well as inorganic arsenic-contaminated drinking water [12, 13, 23]. In a recent study investigating the arsenic metabolites in urine samples of 75 inorganic arsenic-exposed women in Bangladesh, thio-DMAV has been shown to be a common metabolite, being detected in 44% of the samples . Furthermore, thio-DMAV might also directly occur in food, which has been postulated before for rice .
Probably because thio-DMAV is not commercially available, in the literature no in vivo toxicity studies for thio-DMAV (except for toxicokinetic studies) and only few in vitro toxicity studies exist. Nevertheless, these few studies point to a quite strong cellular toxicity of thio-DMAV in mammalian cells in culture. Thus, in most studies, thio-DMAV showed much higher cytotoxicity as compared to MMAV and/or DMAV [23, 25] and comparable effects to trivalent arsenicals [26, 27]. In some studies, thio-DMAV even exerted stronger cytotoxicity as compared to arsenite [27–29]. Moreover, Ochi et al. provided evidence for a genotoxic potential of thio-DMAV in cultured hamster cells , whereas no detailed data exist regarding the genotoxicity of thio-DMAV in human cells.
The aim of the present study was to further investigate the toxicity of thio-DMAV in cultured human A549 lung cells. Therefore, we synthesised and analytically characterised highly pure dimethylthioarsinic anhydride, which in aqueous solution immediately forms thio-DMAV. Subsequently, cytotoxicity, cellular uptake, as well as for the first time genotoxicity at the DNA and chromosomal levels were examined in cultured human cells, while comparing effects of thio-DMAV with effects of arsenite, MMAIII, DMAIII, MMAV, and DMAV.
2. Materials and Methods
Inorganic arsenic is classified as a human carcinogen. The following chemicals are hazardous and should be handled with care: sodium arsenite, methyloxoarsine (precursor to MMAIII), iododimethylarsine (precursor to DMAIII), dimethylthioarsenic anhydride (precursor to thio-DMAV), MMAV, and DMAV.
Dulbecco’s modified Eagle medium (DMEM), foetal calf serum (FCS), trypsin, and penicillin-streptomycin solutions were obtained from Sigma-Aldrich (Steinheim, Germany). The culture dishes were supplied by Biochrom (Berlin, Germany). Sodium(meta)arsenite (≥99% purity) and Alcian Blue were purchased from Fluka Biochemika (Buchs, Germany). Methyloxoarsine (CH3AsIIIO, ≥99% purity) and iododimethylarsine [(CH3)2AsIIII, ≥99% purity] (storage at −80°C) were kindly provided by Professor Dr. W. Cullen (University of British Columbia, Vancouver, Canada). DMAV (≥99% purity) and MMAV (99% purity) were purchased from Sigma-Aldrich (Steinheim, Germany). A549 cells (CCL-185) were obtained from the American Type Culture Collection (Bethesda, MD, USA).
Giemsa dye and acridine orange were bought from Roth (Karlsruhe, Germany). The ICPMS elemental standard (As, 1 mg/L) was purchased from SPETEC (Erding, Germany). Hydrogen peroxide solution (30%, Suprapur) and nitric acid (65%, Suprapur) were products of Merck (Darmstadt, Germany). Triton X-100 was bought from Pierce (Oud-Beijerland, The Netherlands), hydroxyapatite (high resolution) from Calbiochem (Bad Soden, Germany) and Hoechst 33258 from Merck (Darmstadt, Germany). All other proanalysis chemicals were obtained from Sigma-Aldrich (Steinheim, Germany) or Merck (Darmstadt, Germany).
2.3. Synthesis of Dimethylthioarsinic Anhydride
Dimethylthioarsinic anhydride, which dissociates in water to thio-DMAV, was synthesized according to Fricke et al. . Briefly, DMAV was dissolved in ethanol (30%) and hydrogen sulfide was bubbled into the solution and stirred over night. After removing the solvent, the residue was extracted with chloroform/water (3 : 1) and the chloroform layer was washed with water to remove the remaining water-soluble arsenic compounds. Finally, the solvent was removed and dimethylthioarsinic anhydride was recrystallized from methanol/hexane.
2.4. Analysis and Purity Control of Dimethylthioarsinic Anhydride
HPLC-FTMS (Thermo Accela, Thermo LTQ Orbitrap XL), HPLC-ICPMS (Shimadzu LC-10, Perkin Elmer ELAN 6000), and electrothermal AAS (Perkin Elmer, AAnalyst 600) were applied for identification and quantification as well as to obtain information about purity of the arsenic species. Thio-DMAV solutions in water were prepared directly for each experiment; in order to compensate for sensitivity differences, the sample used for HPLC-FTMS (20 mg/L) was diluted by a factor of 400 for HPLC-ICPMS analysis. Briefly, for chromatographic separation, PTFE autosampler vials, a reversed-phase column (Waters Atlantis T3, mm, 5 μm), and the eluent 13.2 mM ammonium acetate in water/10% methanol (pH 4.6)  were used. The flow rate was 0.3 mL/min. The m/z range for HPLC-FTMS analysis was set from m/z 80 to 1000. Fragmentation experiments were carried out with collisionally induced dissociation (CID) using normalized collision energy, and data analysis was performed using Xcalibur software. For quantification of arsenic species by HPLC-ICPMS, chromatographic data were collected by monitoring m/z 75 (As and 40Ar35Cl) and 77 (40Ar37Cl) with 100 ms dwell time. The results of the chromatography were analyzed with the data analysis software from OriginLab. Quantification of total As in thio-DMAV solutions was carried out by electrothermal AAS, applying an ICPMS elemental standard.
Furthermore, 1H-NMR spectroscopy (Bruker DCX-400, 400 MHz) was used to obtain additional purity information. Arsenic species were dissolved in deuterium oxide (D2O), and the chemical shift values were observed for structural information. The obtained results were evaluated with the NMR data software MestReNova (Mestrelab Research) and compared with data from the literature.
2.5. Cell Culture and Incubation with the Arsenicals
Since the lung is an important target organ for inorganic arsenic-induced carcinogenicity, human A549 epithelial lung adenocarcinoma cells were used as in vitro model system. A549 cells were grown in culture dishes as monolayer in DMEM containing 10% FCS, 100 U penicillin/mL, and 100 μg streptomycin/mL. The cultures were incubated at 37°C with 5% CO2 in air and 100% humidity.
Arsenical stock solutions were prepared in sterile deionised water. All stock solutions were prepared shortly before each experiment, among others to prevent oxidation of trivalent arsenicals. Logarithmically growing A549 cells were incubated with the arsenicals for 1 h or 24 h as described for the respective experiments.
2.6. Cytotoxicity Testing of Thio-DMAV
The cytotoxicity of thio-DMAV was elucidated by quantifying its effect on cell number and colony forming ability. Cell number and colony forming ability testing were exactly performed as described before for inorganic arsenic, MMAIII, DMAIII, MMAV, and DMAV . Briefly, after 24 h of incubation with the respective arsenicals, cells were washed with phosphate buffered saline (PBS) and trypsinized. Subsequently, cell number and cell volume were measured by an automatic cell counter (Casy-1, Roche Innovatis AG, Bielefeld, Germany). These measurements are based on noninvasive (dye-free) electrical current exclusion with signal evaluation via pulse area analysis. To assess the impact of thio-DMAV on colony forming ability of A549 cells, after cell counting of each sample, 300 cells/dish were seeded. After 7 days of incubation, colonies were fixed with ethanol, stained with Giemsa (25% in ethanol), counted and calculated as percent of control.
2.7. Cellular Bioavailability
To compare cellular bioavailability of thio-DMAV with cellular bioavailability of inorganic arsenic and its related methylated metabolites, cellular bioavailability studies were carried out by exactly the same protocol as previously reported . Briefly, logarithmically growing cells () were exposed to thio-DMAV for 24 h, trypsinized, collected by centrifugation, washed with ice-cold PBS, and cell number as well as cell volume were measured by an automatic cell counter in each sample as described before. After incubation with the ashing mixture (65% HNO3/30% H2O2 (1/1, v/v)) at 95°C for at least 12 h, samples were diluted with bidistilled water, and arsenic was measured by electrothermal atomic absorption spectrometry (AAnalyst 600, Perkin Elmer).
2.8. Determination of DNA Strand Breaks
DNA strand breaks were quantified by alkaline unwinding as described previously . Briefly, cells were seeded, allowed to attach for 24 h and incubated with thio-DMAV for 1 or 24 h. Subsequently, the medium was removed, cells were washed with PBS and an alkaline solution containing 0.03 M NaOH, 0.02 M Na2HPO4, and 0.9 M NaCl was added. After neutralisation and sonication, separation of single- and double-stranded DNA was performed on 0.5 mL hydroxyapatite columns at 60°C. Single- and double-stranded DNA were eluted with 1.5 mL of 0.15 M and 0.35 M potassium phosphate buffer, respectively. The DNA content of both fractions was determined by adding Hoechst 33258 dye to a final concentration of M to 1 mL of each sample and measuring the fluorescence with a microtiter fluorescence reader (FLUOstar Optima, BMG Labtechnologies, Jena, Germany) at an excitation wavelength of 360 nm and an emission wavelength of 455 nm. DNA strand breaks were quantified by calibration with X-rays as described previously .
2.9. Formation of Micronuclei and Multinucleated Cells
By the early 1990s, the micronucleus assay was shown to be suitable to investigate arsenic-induced chromosomal alterations as a biological marker of its genotoxicity . In recent years, the in vitro micronucleus assay has become an attractive tool for genotoxicity testing in general . Therefore, this endpoint has been (and is) strongly used to characterize the genotoxic potential of arsenicals in epidemiological studies [36, 37] as well as in cultured mammalian cells (e.g., ). To investigate the induction of micronuclei and multinucleated cells, in this study A549 cells were seeded in 6-well plates on Alcian blue coated glass coverslips. After 24 h, cells were incubated with the respective arsenicals for 24 h, fixed with an ice-cold fixation solution (90% methanol/10% PBS, −20°C) for 10 min, dried in the air at room temperature, stained with acridine orange (125 mg/L in PBS) for 10 s, and finally analyzed by fluorescence microscopy. Per coverslip, at least 1000 cells were counted and categorized in mononucleated, binucleated, and multinucleated cells as well as cells with and without micronuclei.
3.1. Synthesis, Analysis and Purity Control of Dimethylthioarsinic Anhydride
Colorless, highly pure dimethylthioarsinic anhydride crystals were obtained by the reaction of DMAV with H2S in ethanol, followed by extraction with chloroform and recrystallisation from methanol/hexane (Figure 1). After dissolving dimethylthioarsinic anhydride in water, formation of thio-DMAV was analysed by means of hyphenated techniques and 1H-NMR.
The mass spectrometric data and the 1H-NMR results confirmed the conversion of the synthesized anhydride in water into the acid form thio-DMAV. Structural elucidation of thio-DMAV was performed by HPLC-FTMS analysis and by determination of the exact mass. The calculated mass of the acid form is m/z 154.9512 [M+H]+ and the detected mass was m/z 154.9509. Fragmentation experiments with collisionally induced dissociation of the parent ion m/z 154.95 [C2H8OAsS]+ gave a fragment ion of m/z 136.9403 [C2H6AsS]+ and further fragmentation led to m/z 108.9089 [H2AsS]+. The corresponding HPLC-FTMS total ion chromatogram (Figure 2(a)) demonstrates thio-DMAV as a protonated molecular ion with a retention time of 7.3 min, whereas neither starting material nor further reaction products were detected.
HPLC-ICPMS analyses further verified the purity of thio-DMAV by retention time matching of known arsenic species, including DMAV as the starting material. Thus, after dissolving thio-DMAV in water, HPLC-ICPMS chromatograms showed only one compound (Figure 2(b)). Under additional consideration of the quantification of thio-DMAV by electrothermal AAS, the purity of dimethylthioarsinic anhydride was assessed to be ≥98%.
1H-NMR measurements of thio-DMAV (Figure 2(c)) in D2O resulted in a chemical shift value of 2.12 ppm which is similar to the value of 2.11 ppm reported by Fricke et al. . DMAV showed a chemical shift of 1.98, the range of which is consistent with a pentavalent arsenical. The 1H-NMR data of thio-DMAV showed no impurities, and the desired compound was obtained in analytically pure form based on 1H-NMR spectroscopy.
3.2. Cytotoxicity of Thio-DMAV
Cytotoxicity of thio-DMAV was determined by investigating its effects on cell number and colony forming ability (Figure 3) after 24 h incubation. The cell volume (Figure 4) was determined as well, however, principally to calculate cellular arsenic concentrations later on. Regarding both endpoints, cell number and colony forming ability, thio-DMAV exerted higher cytotoxicity as compared to arsenite and especially to the pentavalent methylated metabolites MMAV and DMAV, whereas effects were about twofold lower as compared to MMAIII and DMAIII (Table 1). Thio-DMAV affected colony forming ability stronger as compared to cell number, which is comparable to the trivalent methylated metabolites. In case of arsenite, MMAV and DMAV, both cytotoxicity endpoints showed similar sensitivity.
3.3. Cellular Bioavailability of Thio-DMAV
To assess cellular bioavailability in A549 cells and to correlate cellular toxicity of thio-DMAV with cellular arsenic content, cellular arsenic concentrations were determined after 24 h incubation by electrothermal atomic absorption spectrometry.
Comparing extracellular and intracellular arsenic concentrations, a 9-10-fold accumulation was observed in cells incubated with up to 15 μM thio-DMAV (Figure 4). Thio-DMAV showed no significant effects on cell volumes (Figure 4) at noncytotoxic concentrations, but increased cell volumes in case of cytotoxic concentrations (≥10 μM) by up to 44%. Mean (±SD) volumes of nonincubated control cells were L.
Interestingly, the concentration of cellular arsenic strongly correlated with the cytotoxicity of thio-DMAV, resulting in a correlation coefficient of −0.986 (cell number) or −0.998 (colony forming ability), respectively.
3.4. Induction of DNA Strand Breaks by Thio-DMAV
A possible generation of DNA strand breaks by thio-DMAV was investigated in A549 cells after short-term (1 h) and long-term (24 h) incubation, applying the alkaline unwinding technique. Up to high, already cytotoxic thio-DMAV concentrations both after 1 h and after 24 h incubation, no significant induction of DNA strand breaks was observed (Figures 5(a) and 5(b)).
3.5. Formation of Micronuclei and Multinucleated Cells by the Arsenicals
The two basic mechanisms leading to the onset of micronuclei are disturbance of the chromosome segregation machinery and chromosome breakage. Thus, in somatic cells, micronuclei can only occur after mitotic division, and in the cytokinesis-block micronucleus assay (CBMN), which is based on cytokinesis inhibition by cytochalasin B, cell proliferation and thereby mitosis are generally controlled by a scoring of mono- and binucleated cells . However, our first CBMN studies indicated that several arsenicals interact with actin and/or the effect of cytochalasin B (data not shown). To assess the induction of micronuclei by the arsenicals, we omitted the application of cytochalasin B. To ensure mitosis, we controlled cell proliferation by means of cell number quantification and chose an incubation time of 24 h, which is equivalent to 1.25 cell cycles of the A549 lung cells. This incubation time was previously used to examine cellular toxicity of arsenicals in A549 cells  and, therefore, opens the possibility to compare results. Furthermore, this protocol allows the proper quantification of the formation of multinucleated cells by the arsenicals at the same time.
At noncytotoxic to beginning slightly cytotoxic concentrations, MMAIII (0.5, 1 μM), thio-DMAV (5 μM), MMAV (250 μM), and DMAV (250 μM) induced a small, but significant number of around 20 micronuclei (Figure 6(a)). At higher, already cytotoxic arsenic species concentrations, micronuclei formation increased and became also significant in case of arsenite (≥50 μM). At highly cytotoxic concentrations, 5 μM DMAIII and 30 μM thio-DMAV showed strongest effects, inducing and micronuclei, respectively.
Moreover, thio-DMAV and especially DMAIII increased the formation of multinucleated cells and the occurrence of binucleated cells in comparison to untreated control cells (Figure 6(b)). However, significant effects were restricted to cytotoxic concentrations. For all other applied arsenicals, no significant increased occurrence of bi- and multinucleated cells was observed.
The data presented in this study provide further evidence for the strong cellular toxicity of the recently identified arsenic metabolite thio-DMAV in human cells.
In the applied human lung cells, cytotoxicity of thio-DMAV strongly correlates with its cellular bioavailability. For other arsenic species, a similar correlation has been reported in A549 cells  as well as in human urothelial (UROtsa) and hepatic (HepG2) cells  before.
When comparing the respective arsenic incubation concentrations, thio-DMAV exerts higher cytotoxicity than arsenite, whereas effects are lower as compared to MMAIII and DMAIII. When additionally taking into account the cellular bioavailability of the arsenicals, among all arsenicals, applied thio-DMAV shows the highest cytotoxicity in A549 cells. For instance, 30% reduction in cell number occurred after 24 h incubation with 5 μM DMAIII, which is related to μM cellular arsenic . 12.1 μM thio-DMAV caused a similar reduction in cell number; however, it corresponds to a cellular arsenic concentration of μM. Thus, a similar cytotoxic effect is achieved at twofold lower cellular arsenic concentrations. In summary, referring to the extracellular incubation concentrations, in A549 human lung cells the arsenicals follow the cytotoxic order: DMAIII > MMAIII > thio-DMAV≫ arsenite ≫ MMAV ~ DMAV. Taking into account the cellular uptake of the arsenic species and thereby referring to the effective cellular arsenic concentrations, the cytotoxic order switches to thio-DMAV~ arsenite ~ MMAIII > DMAIII ≫ MMAV ~ DMAV. This is somehow contrary to the study by Naranmandura et al. , where at the respective IC50 concentrations, cellular thio-DMAV uptake was higher as compared to DMAIII and arsenite uptake. This different outcome might be due to the different cell systems applied, but most likely results from the different cytotoxicity endpoints investigated. By using the MTT test, Naranmandura et al. used a cellular metabolism-related cytotoxicity endpoint, which quantifies the impact of the arsenicals on the activity of cellular dehydrogenases. In contrast, in this study we quantified cell number, which comprises cell death and proliferation inhibition by the arsenicals. Moreover, colony forming ability, which is generally considered as benchmark long term-cytotoxicity assay for directly not acute cytotoxic compounds, was applied as second cytotoxicity endpoint. Very interestingly, thio-DMAV exerts stronger cytotoxicity regarding the endpoint colony forming ability, which points to an indirect mode of toxic action. This has similarly been shown before for the trivalent methylated metabolites .
In contrast to all other methylated arsenic metabolites , in A549 cells thio-DMAV showed no generation of DNA strand breaks up to high cytotoxic concentrations. This is also in line with the fact that thio-DMAV did not significantly increase reactive oxygen species level in A549 cells (as assessed by DCFDA fluorescence) up to high cytotoxic concentrations (data not shown). This is in contrast to the postulated, reactive oxygen species-mediated toxic mode of action of thio-DMAV [28, 40]. Accordingly thio-DMAV, as well as DMAIII and arsenite, exerted strong genotoxicity on the chromosomal level only at cytotoxic concentrations. Thus, in the present study, MMAIII is the only arsenical-inducing micronuclei at noncytotoxic, exposure-relevant concentrations starting at 0.5 μM. Micronuclei formation in A549 cells results at least partly from the earlier observed induction of DNA damage by 0.5 μM MMAIII .
For DMAIII, micronuclei induction has been shown before in CHO cells  and is discussed to be due to both aneugenic and clastogenic effects of DMAIII. In SHE (Syrian hamster embryo) cells after 24 h incubation, 20 μM thio-DMAV induced chromosome structural aberrations including chromatid gaps, chromatid break and chromatid changes . This fits nicely to earlier data by Kuroda et al. in V79 Chinese hamster lung cells: here, the unknown microbial metabolite of DMAV, which is nowadays strongly discussed to be thio-DMAV, induced chromosomal aberrations as well as sister chromatid exchange, mitotic arrest, and tetraploids . In this study, thio-DMAV and especially DMAIII additionally increased the formation of multinucleated and binucleated cells, which most probably results from spindle abnormalities induced by these arsenic species [25, 42]. Furthermore, the increased formation of binucleated cells indicates an inhibitory effect of DMAIII and thio-DMAV on cytokinesis. Accordingly, in the same concentration range, both arsenicals caused a G2/M cell cycle phase arrest after 24 h incubation in A549 cells (data not shown). For thio-DMA, this has already been shown before in human HepG2 hepatocarcinoma cells  and A431 epidermoid carcinoma cells .
When rating the formation of micronuclei, micronucleated and binucleated cells, it once again has to be clearly stated that all these effects were restricted to high concentrations of arsenite, thio-DMAV, and DMAIII. Strong effects were observed exclusively for DMAIII, with a sevenfold increase in micronuclei induction, a tenfold increased occurrence of binucleated cells, and an 80-fold increase in multinucleated cells after 24 h incubation with 5 μM DMAIII. Thus, in case of DMAIII, these effects most likely trigger DMAIII cytotoxicity, especially regarding the endpoint colony forming ability. This is unlikely for thio-DMAV and even more unlikely for arsenite.
In summary, thio-DMAV seems to exert its high cellular toxicity by a different mode of action than arsenite, MMAIII, and DMAIII. Our data strongly indicate that in human A549 lung cells, thio-DMAV does not act via a genotoxic mode of action. Nevertheless, to assess the role of thio-DMAV in inorganic arsenic-induced carcinogenicity, to date still too little is known about thio-DMAV. This is particularly valid as thio-DMAV is a human metabolite not only of inorganic arsenic but also of seafood related organic arsenicals, which indicates that further mechanistic studies are urgently needed to identify its toxic mode of action and finally assess the potential implications for human health.
Conflict of Interests
The authors declare that they have no conflict of interests.
The authors would like to thank Professor Dr. W. R. Cullen (Vancouver, Canada) for kindly providing the trivalent methylated arsenic metabolites as well as the Ph.D. student Miriam Schwarzer (Analytical Chemistry, WWU Muenster) for helpful discussions, with respect to LC-ICPMS measurements, and the master students Imke Pieper, Friederike Schwartz, and Anika Prause (Food Chemistry, WWU Muenster) for their practical work in the laboratory. The authors especially thank the team of Professor Dr. H.-U. Humpf (Food Chemistry, WWU Muenster) for helpful discussions with respect to HPLC-FTMS and 1H-NMR analyses. They acknowledge support by Deutsche Forschungsgemeinschaft (DFG) and Open Access Publication Fund of University of Muenster. This work was supported by the DFG Grant number SCHW 903/3-2 and SCHW 903/4-1. Marc Bartel and Franziska Ebert contributed equally to the practical work in this study.
- IARC, ARC Monographs on the Evaluation of Carcinogenic Risks to Humans Supplement 7, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, International Agency for Research on Cancer, Lyon, France, 1987.
- K. Straif, L. Benbrahim-Tallaa, R. Baan et al., “A review of human carcinogens—part C: metals, arsenic, dusts, and fibres,” The Lancet Oncology, vol. 10, no. 5, pp. 453–454, 2009.
- K. T. Kitchin and K. Wallace, “Evidence against the nuclear in situ binding of arsenicals-oxidative stress theory of arsenic carcinogenesis,” Toxicology and Applied Pharmacology, vol. 232, no. 2, pp. 252–257, 2008.
- A. de Vizcaya-Ruiz, O. Barbier, R. Ruiz-Ramos, and M. E. Cebrian, “Biomarkers of oxidative stress and damage in human populations exposed to arsenic,” Mutation Research, vol. 674, no. 1-2, pp. 85–92, 2009.
- S. J. Flora, “Arsenic-induced oxidative stress and its reversibility,” Free Radical Biology and Medicine, vol. 51, no. 2, pp. 257–281, 2011.
- K. Jomova, Z. Jenisova, M. Feszterova et al., “Arsenic: toxicity, oxidative stress and human disease,” Journal of Applied Toxicology, vol. 31, no. 2, pp. 95–107, 2011.
- X. Ren, C. M. Mchale, C. F. Skibola, A. H. Smith, M. T. Smith, and L. Zhang, “An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis,” Environmental Health Perspectives, vol. 119, no. 1, pp. 11–19, 2011.
- A. Hartwig and T. Schwerdtle, “Arsenic induced carcinogenicity: new insights in molecular mechanisms,” in Metal-Complex DNA Interactions, N. Hadjiliadis and E. Sletten, Eds., pp. 491–510, John Wiley and Sons, 2009.
- EFSA, “Scientific opinion on arsenic in food. EFSA panel on contaminants in the food chain,” EFSA Journal, vol. 7, no. 10, article 1351, pp. 1–198, 2009.
- JECFA, “Evaluation of certain food additives and contaminants,” WHO Food Additive Report Series 18, International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland, 1983.
- JECFA, “Evaluation of certain food additives and contaminants,” WHO Food Additive Report Series 24, International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland, 1989.
- R. Raml, W. Goessler, P. Traar, T. Ochi, and K. A. Francesconi, “Novel thioarsenic metabolites in human urine after ingestion of an arsenosugar, ,-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-β-D-riboside,” Chemical Research in Toxicology, vol. 18, no. 9, pp. 1444–1450, 2005.
- R. Raml, G. Raber, A. Rumpler, T. Bauernhofer, W. Goessler, and K. A. Francesconi, “Individual variability in the human metabolism of an arsenic-containing carbohydrate, ,-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-β-D-riboside, a naturally occurring arsenical in seafood,” Chemical Research in Toxicology, vol. 22, no. 9, pp. 1534–1540, 2009.
- M. J. Mass, A. Tennant, B. C. Roop et al., “Methylated trivalent arsenic species are genotoxic,” Chemical Research in Toxicology, vol. 14, no. 4, pp. 355–361, 2001.
- M. Nollen, F. Ebert, J. Moser, L. H. F. Mullenders, A. Hartwig, and T. Schwerdtle, “Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression,” Molecular Nutrition and Food Research, vol. 53, no. 5, pp. 572–582, 2009.
- J. S. Petrick, F. Ayala-Fierro, W. R. Cullen, D. E. Carter, and H. Vasken Aposhian, “Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes,” Toxicology and Applied Pharmacology, vol. 163, no. 2, pp. 203–207, 2000.
- T. Schwerdtle, I. Walter, and A. Hartwig, “Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg,” DNA Repair, vol. 2, no. 12, pp. 1449–1463, 2003.
- T. Schwerdtle, I. Walter, I. Mackwin, and A. Hartwig, “Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured huma cells and isolated DNA,” Carcinogenesis, vol. 24, no. 5, pp. 967–974, 2003.
- M. Styblo, L. M. del Razo, L. Vega et al., “Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells,” Archives of Toxicology, vol. 74, no. 6, pp. 289–299, 2000.
- I. Walter, T. Schwerdtle, C. Thuy, J. L. Parsons, G. L. Dianov, and A. Hartwig, “Impact of arsenite and its methylated metabolites on PARP-1 activity, PARP-1 gene expression and poly(ADP-ribosyl)ation in cultured human cells,” DNA Repair, vol. 6, no. 1, pp. 61–70, 2007.
- T. S. Wang, C. H. Chung, A. S. S. Wang et al., “Endonuclease III, formamidopyrimidine-DNA glycosylase, and proteinase K additively enhance arsenic-induced DNA strand breaks in human cells,” Chemical Research in Toxicology, vol. 15, no. 10, pp. 1254–1258, 2002.
- H. R. Hansen, A. Raab, M. Jaspars, B. F. Milne, and J. Feldmann, “Sulfur-containing arsenical mistaken for dimethylarsinous acid [DMA(III)] and identified as a natural metabolite in urine: major implications for studies on arsenic metabolism and toxicity,” Chemical Research in Toxicology, vol. 17, no. 8, pp. 1086–1091, 2004.
- R. Raml, A. Rumpler, W. Goessler et al., “Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh,” Toxicology and Applied Pharmacology, vol. 222, no. 3, pp. 374–380, 2007.
- A. H. Ackerman, P. A. Creed, A. N. Parks et al., “Comparison of a chemical and enzymatic extraction of arsenic from rice and an assessment of the arsenic absorption from contaminated water by cooked rice,” Environmental Science and Technology, vol. 39, no. 14, pp. 5241–5246, 2005.
- T. Ochi, K. Kita, T. Suzuki, A. Rumpler, W. Goessler, and K. A. Francesconi, “Cytotoxic, genotoxic and cell-cycle disruptive effects of thio-dimethylarsinate in cultured human cells and the role of glutathione,” Toxicology and Applied Pharmacology, vol. 228, no. 1, pp. 59–67, 2008.
- H. Naranmandura, K. Ibata, and K. T. Suzuki, “Toxicity of dimethylmonothioarsinic acid toward human epidermoid carcinoma A431 cells,” Chemical Research in Toxicology, vol. 20, no. 8, pp. 1120–1125, 2007.
- S. Suzuki, L. L. Arnold, K. L. Pennington et al., “Dietary administration of sodium arsenite to rats: relations between dose and urinary concentrations of methylated and thio-metabolites and effects on the rat urinary bladder epithelium,” Toxicology and Applied Pharmacology, vol. 244, no. 2, pp. 99–105, 2010.
- H. Naranmandura, Y. Ogra, K. Iwata et al., “Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells,” Toxicology and Applied Pharmacology, vol. 238, no. 2, pp. 133–140, 2009.
- J. Chilakapati, K. Wallace, H. Ren et al., “Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid,” Toxicology, vol. 268, no. 1-2, pp. 31–39, 2010.
- M. Fricke, M. Zeller, W. Cullen, M. Witkowski, and J. Creed, “Dimethylthioarsinic anhydride: a standard for arsenic speciation,” Analytica Chimica Acta, vol. 583, no. 1, pp. 78–83, 2007.
- F. Ebert, A. Weiss, M. Bültemeye, I. Hamann, A. Hartwig, and T. Schwerdtle, “Arsenicals affect base excision repair by several mechanisms,” Mutation Research, vol. 715, no. 1-2, pp. 32–41, 2011.
- J. Bornhorst, F. Ebert, A. Hartwig, B. Michalke, and T. Schwerdtle, “Manganese inhibits poly(ADP-ribosyl)ation in human cells: a possible mechanism behind manganese-induced toxicity?” Journal of Environmental Monitoring, vol. 12, no. 11, pp. 2062–2069, 2010.
- A. Hartwig, U. D. Groblinghoff, D. Beyersmann, A. T. Natarajan, R. Filon, and L. H. F. Mullenders, “Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts,” Carcinogenesis, vol. 18, no. 2, pp. 399–405, 1997.
- A. H. Smith, C. Hopenhayn-Rich, M. Warner, M. L. Biggs, L. Moore, and M. T. Smith, “Rationale for selecting exfoliated bladder cell micronuclei as potential biomarkers for arsenic genotoxicity,” Journal of Toxicology and Environmental Health, vol. 40, no. 2-3, pp. 223–234, 1993.
- M. Kirsch-Volders, G. Plas, A. Elhajouji et al., “The in vitro MN assay in 2011: origin and fate, biological significance, protocols, high throughput methodologies and toxicological relevance,” Archives of Toxicology, vol. 85, no. 8, pp. 873–899, 2011.
- C. J. Chen, L. I. Hsu, C. H. Wang et al., “Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan,” Toxicology and Applied Pharmacology, vol. 206, no. 2, pp. 198–206, 2005.
- P. Ghosh, A. Basu, K. K. Singh, and A. K. Giri, “Evaluation of cell types for assessment of cytogenetic damage in arsenic exposed population,” Molecular Cancer, vol. 7, article 45, 2008.
- E. Dopp, L. M. Hartmann, A. M. Florea et al., “Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells,” Toxicology and Applied Pharmacology, vol. 201, no. 2, pp. 156–165, 2004.
- E. Dopp, U. von Recklinghausen, R. Diaz-Bone, A. V. Hirner, and A. W. Rettenmeier, “Cellular uptake, subcellular distribution and toxicity of arsenic compounds in methylating and non-methylating cells,” Environmental Research, vol. 110, no. 5, pp. 435–442, 2010.
- H. Naranmandura, N. Suzuki, K. Iwata, S. Hirano, and K. T. Suzuki, “Arsenic metabolism and thioarsenicals in hamsters and rats,” Chemical Research in Toxicology, vol. 20, no. 4, pp. 616–624, 2007.
- K. Kuroda, K. Yoshida, M. Yoshimura et al., “Microbial metabolite of dimethylarsinic acid is highly toxic and genotoxic,” Toxicology and Applied Pharmacology, vol. 198, no. 3, pp. 345–353, 2004.
- A. D. Kligerman, C. L. Doerr, and A. H. Tennant, “Oxidation and methylation status determine the effects of arsenic on the mitotic apparatus,” Molecular and Cellular Biochemistry, vol. 279, no. 1-2, pp. 113–121, 2005.
Copyright © 2011 Marc Bartel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.